tbuckley/cabot-search huggingface dataset:
Importance of Determining Maximal Heart Rate for Providing a Standardized Training Stimulus
Authors: Dominik Pesta, Martin Burtscher
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Anti-Drug Antibody Responses to Lumiliximab Are Not Detected in Relapsed Refractory CLL Patients Treated with Lumiliximab in Combination with FCR in a Phase 1/II Study
Authors: Julie Ranuio, Annalee Estrellado, Sarah Harris, Megan Shannon, Meena Subramanyam, Steve Hughes, James Woodworth, Shabnam Tangri
Journal: Blood (2008)
Role of CCABE regimen in locally advanced and metastatic sarcomas.
Authors: A. I. Masood, S. A. Gurchani, A. Anwer
Journal: Journal of Clinical Oncology (2011)

e20526 Background: Sarcomas are the rare malignancies all over the world. Most of the patients present with locally advanced disease even with metastasis. Primary therapy is surgery, but it is usually not possible due to the advanced status of the disease. Data is deficient for chemotherapeutic regimens, to be used as neo-adjuvant chemotherapy for advanced (unresectable) sarcomas. We evaluated the role of combination of various chemotherapeutic agents, effective against sarcoma used in various trials. These agents were used in a combination of cisplatin, cyclophosphamide, adriamycin, bleomycin, etoposide (CCABE) for the treatment of sarcomas, for down staging as well as resolving of metastasis. Methods: In this retrospective study, 150 patients of sarcomas with advanced stage or metastasis were evaluated who received this combination of CCABE from 2000 to 2009 (ten years). The primary end point was to assess the response to therapy regarding resolving of metastasis and whether surgical resection was possible. Results: Patients received three to six cycles (median=4) of CCABE regimen. All patients tolerated chemotherapy regimen well with no documented chemotherapy related mortality. Twenty eight (18%) patients showed complete response, ninty six (64%) patients showed partial response, fifteen (10%) had stable disease and eleven (07%) patients had progressive disease. One hundred and twenty (80%) patients underwent surgery after neo adjuvant chemotherapy. Eighty one (67%) patients underwent complete resection and partial resection was done in thirty nine (32%) patients. After surgery twenty six (17%) patients received further chemotherapy. Seventy eight (65%) patients having done surgery also received locoregional radiation therapy. Mostly grade III, IV mucositis and vomiting ware observed during treatment. Conclusions: Neo-adjuvant chemotherapy with combination of CCABE regimens seems to be effective in down staging the locally advanced and metastatic sarcomas and rendering surgery possible. A randomized trial comparing with standard regimen will be more appropriate to define the optimum use of this regimen in routine practice.
Reversal of the Antithrombotic Action of Rivaroxaban and Dabigatran: A Clinical Study in Healthy Volunteers.
Authors: Ana M Galan, Eduardo Arellano-Rodrigo, Victoria Veronica Sanz, Patricia Molina, Joan Carles Reverter, Xavier Carné, Jaume Villalta, Dolors Tassies, Maribel Diaz-Ricart, Gines Escolar
Journal: Blood (2012)
Abstract 10259: Echocardiographic Predictors of Mortality in Adults With a Fontan Circulation
Authors: Rachael Cordina, Katherine von Klemperer, Aleksander Kempny, Roxy Senior, David S Celermajer, Sonya Babu-Narayan, Michael Gatzoulis, Wei Li
Journal: Circulation (2015)

Introduction: Transthoracic echocardiographic (TTE) parameters that predict mortality have not been well-defined in Fontan-adults. Atrioventricular valve systolic to diastolic duration ratio (AVV S:D) is an echocardiographic indice that reflects global cardiac performance but has not been studied in this setting. AVV S:D may be useful in this heterogeneous group as it does not rely on geographic assumption or segmental analysis. Methods: Fontan-adults (≥18 years) in sinus or A-paced V-sensed rhythm seen at our institution since 2005 were studied prospectively. Clinical data were recorded from time of index TTE. Subjects were censored at death or most recent review. Nil had cardiac transplant. Results: In total, 128 patients (64 male) were included, mean age was 27 ± 8 years, 107 had dominant left ventricle (LV), 18 had dominant right ventricle (RV) and 3 were biventricular with large ventricular septal defect. Forty-eight had atriopulmonary connection (APC), 64 had total cavopulmonary connection (TCPC) and 16 had TCPC conversion. Time since first repair was 22 ± 7 years. Mean NYHA Class was 1.4 ± 0.6. During mean follow-up of 4.3 ± 2.8 years, 12 patients died (1 dominant RV, 11 dominant LV). Eight deaths were due to heart failure, 2 were sudden death and 2 were due to liver failure. In univariate analysis the strongest TTE predictors of mortality were AVV S:D, presence of restrictive filling using pulse and tissue Doppler parameters, subjective grade of systolic ventricular function, fractional area change and moderate to severe AVV regurgitation. Results with p ≤ 0.2 are shown in Figure 1. Cox regression analysis suggested NYHA Class and AVV S:D were independent predictors of mortality (p&lt;0.0001 for both). Conclusions: TTE indices are predictive of mortality in Fontan-adults. Ventricular performance assessed by AVV S:D was the most important parameter and should be incorporated into routine clinical assessment of these patients.
GCS-100, a Galectin 3 Antagonist, Is a Novel Caspase-9 Apoptosis Activating Agent for the Treatment of Indolent B-Cell Malignancies.
Authors: Finbarr E. Cotter, Bo Su, Margherita Corbo, Y. Chang, Joanne Schindler, Brad Carver, Christopher D. Fegan, Adrian C. Newland, Rebecca L. Auer
Journal: Blood (2004)
Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML)
Authors: Raphael Itzykson, Olivier Kosmider, Aline Renneville, Margot Morabito, Céline Berthon, Lionel Ades, Pierre Fenaux, Odile Beyne-Rauzy, Thorsten Braun, Francois Dreyfus, Nicholas C.P. Cross, Claude Preudhomme, Olivier A. Bernard, Michaela Fontenay, William Vainchenker, Nathalie Droin, Eric Solary
Journal: Blood (2012)
Lower urinary tract morbidity after prostate brachytherapy with cesium-131.
Authors: R. Smith, S. Beriwal, J. Vargo, R. M. Benoit
Journal: Journal of Clinical Oncology (2011)

97 Background: Cesium-131 is a relatively new radioisotope for prostate brachytherapy (PB), with limited long-term data for toxicity profiles. Here we report our 1-year follow up for severity and time to resolution of lower urinary tract toxicity using American Urological Association (AUA) and Expanded Prostatic Cancer Index Composite (EPIC) scoring. Methods: 186 patients with prostate cancer [NCCN risk category: Low (n=79), Intermediate (n=83), and High (n=24)] treated with cesium-131 PB alone (n=128) or combined with external beam radiation therapy (EBRT) + PB (n=58) were followed as part of a longitudinal prospective study. Patients completed AUA and EPIC surveys pre-operatively and at 2 weeks, 4 weeks, 3, 6, 9, and 12 months post-operatively. The mean prostatic volume was 41.3 cm 3 (range 14.9 – 89.1) and the mean prostate D90 and V100 were 105.7% and 92.4%, respectively. Outcomes were analyzed using descriptive statistics and student t-tests, with an AUA score increase &gt; 4 and EPIC score decrease &gt; 10 points considered clinically significant. Results: Results are shown in the table below. As expected, there was acute urinary toxicity associated with PB. This is seen in the urinary summary score as well as in every one of the subset scales. These were most significant at the 2 and 4 week marks. The urinary summary score and every subscale improved to within 10 points of baseline by 3 months and stayed there through the 12 months of follow-up. Similar findings were reflected in the AUA scores. Conclusions: For men undergoing PB with cesium-131, results for AUA and EPIC scoring are concordant with no clinically significant differences in lower urinary tract symptoms are observed after 3 months relative to pre-operative values. The largest decreases in symptomatology scoring were witnessed in the irritative/obstructive subset, while the smallest changes relative to pre-operative values were noted in the incontinence subset. [Table: see text] No significant financial relationships to disclose.
Laser Surface Pattering of Titanium for Improving the Biological Performance of Dental Implants
Authors: Christoph Zwahr, Denise Günther, Tina Brinkmann, Nikolai Gulow, Steffen Oswald, Marzellus Grosse Holthaus, Andrés Fabián Lasagni
Journal: Advanced Healthcare Materials (2016)

Direct laser interference patterning (DLIP) is used to produce periodic line-like patterns on titanium surfaces. An Nd:YAG laser operating at 532 nm wavelength with a pulse duration of 8 ns is used for the laser patterning process. The generated periodic patterns with spatial periods of 5, 10, and 20 µm are produced with energy densities between 0.44 and 2.6 J cm-2 with a single laser pulse. With variation of energy density, different shapes of the arising topography are observed due to the development of the solidification front of the molten material at the maxima positions. Characterization of the surface chemistry shows that the DLIP treatment enhances the content of nitrogen of the titanium reactive layer from 3.9% up to 23.4%. The structural analysis near the titanium surface shows no changes in microstructure after the laser treatment. Contact angles between 65° and 79° are measured on both structured and turned reference surfaces. Cell viability of human osteoblasts on line-like patterned surfaces after 7 d in cultivation medium is 16% higher compared to the grit-blasted and acid-etched references. Finally, the possibility of patterning complex 3D dental implants is shown.
A gene expression signature to predict high-grade prostate cancer response to oxaliplatin.
Authors: Philippe Pourquier, Stephane Puyo, Pierre Richaud, Jacques Robert, Nadine Houede
Journal: Journal of Clinical Oncology (2012)

150 Background: Prostate cancer (PCa) is one of the leading causes of death from cancer in men. High Gleason grade prostate cancers are characterized by aggressive tumors with poorly differentiated cells and a high metastatic potential. They are often refractory to chemical castration but still treated with hormone therapy to which docetaxel or cabazitaxel are added when they become resistant to the anti-androgen. Despite many clinical trials with other chemotherapeutic agents, response rates remain low. Moreover, none of these trials took into account the tumor grade. Methods: We used an in silico approach to screen for drug candidates that could be used as an alternative to taxanes, based on a 86 genes signature which could distinguish between low-grade and high-grade tumors. We extracted from the NCI60 panel databases the expression profiles of the 86 genes across 60 human tumor cell lines and the corresponding in vitro cytotoxicity data of 152 drugs and looked for correlation between their expression level and cell sensitivity to each of these drugs. Results: Among the 86 genes, we identified 9 genes (PCCB, SHMT2, DPM1, RHOT2, RPL13, CD59, EIF4AI, CDKN2C, JUN) for which expression levels across the 60 cell lines was significantly correlated (p&lt; 0.05) to oxaliplatin but not to cisplatin sensitivity. This signature was validated at the functional level since repression of each of these genes conferred a significant change in the sensitivity of PCa cell lines to oxaliplatin but not cisplatin. Conclusions: Our results provide a proof of concept that gene expression signature specific from high grade PCa could be used for the identification of alternative therapies to taxanes. They could also be used to select patients for further clinical trials and as predictive markers of response to these drugs, which represents a further step forward towards personalized therapy of PCa.
The effect of total lymph nodes removed and the lymph node ratio on overall survival in resected pancreatic cancer.
Authors: Christina Wai, Karthik Devarajan, John Parker Hoffman
Journal: Journal of Clinical Oncology (2012)

371 Background: Previous studies evaluating lymph node status in pancreatic cancer have demonstrated that the ratio of positive nodes to total numbers resected is an important prognostic factor for survival. In our study we sought to see if the total number of nodes removed and lymph node ratio (LNR) would influence overall survival. Methods: A retrospective chart review of 210 patients from July 1998 to July 2011 who underwent resection of pancreatic adenocarcinoma was done. Patients were evaluated for demographic information, neoadjuvant therapy status, surgical margins, pathological stage, total number of lymph nodes retrieved and the number of positive lymph nodes. The LNR was calculated by taking the number of positive lymph nodes to the total number of lymph nodes retrieved. The endpoint evaluated was overall survival (OS). Results: Of the 210 patients, 107 (51%) were male and 103 (49%) were female. The median age was 68. A total of 110 patients had 1 or more positive nodes. The median number of nodes evaluated for all patients was 15 (range 2-51) and the median number of positive lymph nodes was 1. In patients with positive lymph nodes, the median LNR was 0.15 or 15%. For the 210 patients, in univariate analysis, there was a statistically significant association between LNR and overall survival. When the LNR reached &gt;11.2%, patient survival was worse (p=0.018). The total number of nodes removed was not significantly associated with OS for those with positive or negative nodes. However, with multivariable CART analysis, taking into account T stage and surgical margins, LNR had a significant impact on overall survival only for patients who had a R0 resection and T0-T2 disease. If there LNR was &gt; 0, survival was better (p=0.043). Conclusions: In certain GI malignancies, complete evaluation of local lymph nodes is important and changes the survival of patients. In T0-T2 stage pancreatic cancer patients resected with negative margins, outcome is worse if there are positive nodes in these patients. Therefore based on our data, the LNR may be useful for determining the prognosis of early T stage cancer patients.
Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) As a Potential Treatment for B-Cell Malignancies
Authors: Victoria Walker, Nicolas E S Guisot, Stuart Best, Fatima Talab, Catherine L Lucas, Julienne Refuerzo, Mathew Calder, Lauren Proctor, Melanie Muller, Kelvin Ho, Rose Chappell, Juliette Emmerich, Shona Harmon, Matilda Bingham, Mary-Ann Campbell, Richard Armer
Journal: Blood (2015)
The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy.
Authors: E. S. Antonarakis, D. Keizman, M. A. Carducci, M. A. Eisenberger
Journal: Journal of Clinical Oncology (2011)

16 Background: We previously reported on a cohort of men with biochemical recurrence after prostatectomy (n=430) who underwent observation until metastatic progression. Here, we describe the PSA at metastasis for those patients who developed metastatic disease. Methods: PSA at metastasis was defined as the PSA value collected at the time of the first occurrence of metastasis as determined by CT or bone scan. We calculated the median PSA at metastasis and the interquartile range (IQR) for the entire cohort of men with metastatic progression, and also across different strata of PSADT (≤3 vs 3-9 vs 9-15 vs ≥15 mo) and Gleason score (≤7 vs 8-10). We used Pearson's correlation coefficient (r) to examine the relationship between PSADT or Gleason score and PSA at metastasis. Results: With a median follow-up of 4 years after biochemical recurrence, 126/430 men (29.3%) had developed metastases. Sites of first metastasis included bone in 114 men (90.5%), extra-pelvic lymph nodes in 5 men (4.0%), lung in 3 men (2.4%), liver in 3 men (2.4%), and brain in 1 man (0.8%). The median PSA at the time of initial metastasis was 31.4 ng/mL (IQR, 8.8–87.5). Median PSA at metastasis across different PSADT strata is shown below (Table). There was a weak but statistically significant correlation between PSADT and 1/PSA at metastasis (r=0.20, P=0.02). There was no correlation between Gleason score and PSA at metastasis (r=0.01, P=0.83). Median PSA at metastasis was 30.3 ng/mL (IQR, 8.6–74.9) for men with Gleason ≤7 (n=69) and 34 ng/mL (IQR, 7.9–115) for men with Gleason 8-10 (n=57). Conclusions: In patients with biochemical recurrence after prostatectomy, there is an inverse correlation between PSADT and PSA at metastasis, while Gleason sum has no effect on PSA at metastasis. These data may be used by clinicians to estimate at what PSA level metastases are likely to first develop across different strata of PSADT, helping to determine when/if to initiate therapy. [Table: see text] No significant financial relationships to disclose.
Correlation of <sup>11</sup>c-choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Authors: A. J. Breeuwsma, J. Pruim, A. M. Leliveld, R. A. Dierckx, I. J. de Jong
Journal: Journal of Clinical Oncology (2011)

123 Background: Restaging with PET-CT in biochemical recurrent prostate cancer after prostatectomy shows a higher frequency of (false) negative cases compared to restaging after EBRT. It is uncertain if this reflects low volume of disease and/or low grade as biopsies fail to prove recurrent cancer in 50% of cases. We followed the clinical course of men with recurrent prostate cancer (PCa) after radical prostatectomy and investigated treatment and survival. PET-CT data were correlated with clinical data, PSA kinetics and disease specific and overall survival. We also studied relative survival comparing an age matched group from the Central Dutch Statistical Office (CBS). Methods: 64 patients underwent 11C-Choline PET-CT on PSA relapse. All patients were initially treated with radical prostectomy and reached PSA nadir of &lt;0.1ng/mL. Recurrent disease was defined as PSA &lt;0.4ng/mL after nadir. Patients were either treated with watchful waiting, adjuvant radiotherapy and/ or androgen deprivation therapy based on individual assesments by the treating urologists. Chi-square, log-rank and Mann-Whitney-U tests were used to study this population Results: The 64 patients had median PSA of 1.4ng/mL. Median follow-up period of patients was 50 (6–124) months. Ten patients died during the course of follow-up of which 5 due to metastasized PCa. No significant differences were seen in age, time to recurrence, total PSA at recurrence and PET-CT results. Patients with abnormal PET had higher PSAVel (median 3.09 ng/mL/yr vs 10.17, p= 0.002) and and shorter PSADT (med 4.83 mo vs 0.53, p= 0.016). Median time to treatment was significantly lower in the PET-CT negative group. Age of patients at death from the whole group did not differ from the age of death in an age matched group. Disease specific survival was significantly higher in the PET-CT negative group (p0.05). Conclusions: A negative 11C-Choline PET-CT correlated with a higher disease specific survival and a lower treatment rate. Overall survival of the group was equal to the age matched cohort. No significant financial relationships to disclose.
The effect of statins on overall survival of breast cancer.
Authors: M. Mozayen, M. Omaira, M. Kanaan, A. Ahmad, K. Katato
Journal: Journal of Clinical Oncology (2011)

34 Background: Observational studies have raised the possibility that use of statins may reduce the incidence and overall risk of cancer. In contrast, some randomized trials have consistently shown no effect of statins at cancer incidence or mortality. However, data about the potential effect of statins on overall survival of breast cancer are limited. We intend to examine the role of statins at overall survival of women diagnosed with breast cancer. Methods: A retrospective observational study was conducted from 1993 to 2007, using data from McLaren Regional Medical Center in Flint, Michigan on women diagnosed with breast cancer. Patient's characteristics including age at diagnosis, race, stage and use of statin with dosage were recorded. Patients with coronary artery disease were excluded to eliminate the confounding effect. The three-year overall survival was considered the primary outcome. Results:s A total of 392 women diagnosed with breast cancer were identified. 146 patients were on statins therapy prior to diagnosis (group 1), and 246 patients were not on statins (group 2). African American percentage was 7%. Mean age at diagnosis was 65 for both groups. Atorvastatin was the most used treatment with a dose of 20 mg daily. Patients were classified according to the TNM staging system of breast cancer as stage I, II, III, IV (58%, 31%, 8%, 3%) for group 1, and (62%, 32%, 4%, 2%) for group 2 respectively. The 3-year stage-specific survivals were calculated and compared between the two groups using Fisher's exact test (Table). Overall survival was not statistically significant between the two groups. Conclusions: Our study did show that statins do not affect the three-year overall survival of breast cancer at early stages, but it may improve the outcome at advanced stages. A larger national data review is warranted. [Table: see text]
Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study
Authors: Stine Ulrik Mikkelsen, Lasse Kjær, Vibe Skov, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A Kruse, Thomas Stauffer Larsen, Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Hans Carl Hasselbalch
Journal: Blood (2015)